Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Axillary Hyperhidrosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2017, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape. Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 1 respectively. Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology). - The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Axillary Hyperhidrosis - Overview Axillary Hyperhidrosis - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Axillary Hyperhidrosis - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Axillary Hyperhidrosis - Companies Involved in Therapeutics Development Allergan Plc Brickell Biotech Inc Dermira Inc Dr. August Wolff GmbH & Co KG Arzneimittle GlaxoSmithKline Plc TheraVida Inc Axillary Hyperhidrosis - Drug Profiles (oxybutynin chloride + pilocarpine hydrochloride) - Drug Profile Product Description Mechanism Of Action R&D Progress botulinum toxinA - Drug Profile Product Description Mechanism Of Action R&D Progress glycopyrrolate - Drug Profile Product Description Mechanism Of Action R&D Progress glycopyrronium tosylate - Drug Profile Product Description Mechanism Of Action R&D Progress sofpironium bromide - Drug Profile Product Description Mechanism Of Action R&D Progress umeclidinium bromide - Drug Profile Product Description Mechanism Of Action R&D Progress Axillary Hyperhidrosis - Dormant Projects Axillary Hyperhidrosis - Discontinued Products Axillary Hyperhidrosis - Product Development Milestones Featured News & Press Releases Mar 21, 2017: Dermira Presents New Data Highlighting Patient Outcomes in Axillary Hyperhidrosis at Maui Derm Meeting Mar 17, 2017: Dermira to Present Data on Glycopyrronium Tosylate Clinical Program at Annual Maui Derm Meeting Mar 03, 2017: Dermira Presents New Data in Primary Axillary Hyperhidrosis at American Academy of Dermatology 2017 Annual Meeting Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis Feb 27, 2017: Dermira Data from DRM04 Clinical Program to Be Presented at American Academy of Dermatology Annual Meeting Oct 13, 2016: Dermira to Present Data from DRM04 Clinical Program at Fall Clinical Dermatology Conference Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis Oct 01, 2016: Dermira Presents Data from DRM04 Phase 3 Clinical Program in Late-Breaking News Session at European Academy of Dermatology and Venereology Congress Sep 28, 2016: Dermira to Present Data from DRM04 Phase 3 Clinical Trials at Late-Breaking News Session at European Academy of Dermatology and Venereology Congress Jun 01, 2016: Dermira Announces Positive Topline Results from Two Pivotal Phase 3 Clinical Trials for DRM04 in Patients with Primary Axillary Hyperhidrosis Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating Feb 29, 2016: Dermira Completes Patient Enrollment for DRM04 Phase 3 Pivotal Trials in Primary Axillary Hyperhidrosis Jan 07, 2016: Dermira Provides DRM04 Development Program Update Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis Aug 03, 2015: Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development for Axillary Hyperhidrosis, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Axillary Hyperhidrosis - Pipeline by Allergan Plc, H2 2017 Axillary Hyperhidrosis - Pipeline by Brickell Biotech Inc, H2 2017 Axillary Hyperhidrosis - Pipeline by Dermira Inc, H2 2017 Axillary Hyperhidrosis - Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittle, H2 2017 Axillary Hyperhidrosis - Pipeline by GlaxoSmithKline Plc, H2 2017 Axillary Hyperhidrosis - Pipeline by TheraVida Inc, H2 2017 Axillary Hyperhidrosis - Dormant Projects, H2 2017 Axillary Hyperhidrosis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.